v3.25.2
Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Mar. 31, 2025
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
  

March 31,

 
     2024 
  

2025

  

(as revised)

 
         

Equity based warrants to purchase common shares

  87,531   4,334 

Convertible Notes - common shares (1)

  -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  25,003   25,003 

Stock options granted under Company's incentive plan

  243,483   100,180 

Series A Warrants

  1,533,096   - 

Representative Warrants

  91,985   - 
         

Total potentially dilutive securities

  1,981,098   162,767 
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
  

Twelve Months Ended March 31, 2024

 
  

Originally Filed

  

Adjusted for 1-for-20 Reverse Stock Split

  

Correction

  

As Revised

 
                 

Net Loss (in thousands)

 $(15,426) $-  $-  $(15,426)

Loss per share - basic and diluted

 $(1.05) $(21.09) $6.27  $(14.82)

Weighted average shares outstanding - basic and diluted

  14,626,282   731,372   309,348   1,040,720 
  

Twelve Months Ended March 31, 2024

 
  

Originally Filed

  

Adjusted for 1-for-20 Reverse Stock Split

  

Correction

  

As Revised

 
                 

Equity based warrants to purchase common shares

  5,744,569   287,231   (282,897)  4,334 

Convertible Notes - common shares

  665,000   33,250   -   33,250 

Convertible Notes - equity-based warrants to purchase common shares

  500,000   25,003   -   25,003 

Stock options granted under Company's incentive plan

  2,003,600   100,180   -   100,180 

Total potentially dilutive securities

  8,913,169   445,664   (282,897)  162,767